Condition: Breast Cancer · Sponsor: Tianjin Medical University Cancer Institute and Hospital
A single-center, real-world study evaluated the clinical outcomes and safety of CDK4/6 inhibitors combined with endocrine therapy in HR+/HER2- advanced breast cancer, and conducted a summary analysis of the clinical treatment options after the progression of CDK4/6 inhibitors.
This description comes directly from the study's public registry record.
Yehui Shi, MD · 022-23340123-3252 · shiyehui@tjmuch.com
Yiran Si, MD · 022-23340123-3252
Always discuss trial participation with your own doctor first.
| Tianjin Medical University Cancer Insititute and Hospital | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07407439